{
    "symbol": "NVCR",
    "quarter": 3,
    "year": 2022,
    "date": "2022-10-27 11:33:03",
    "content": " The new U.S. central nervous systems cancers franchise combines sales, marketing and medical leadership under one umbrella; and strengthens our focus on driving adoption of TTFields for newly diagnosed GBM and our largest and most important market. So I mean we've never broken down at -- a detailed quantification but what we have seen is a benefit throughout 2023 and in 2022 from aged claims in the U.S. That's around $10 million a quarter, if you want a round number that I would look."
}